Intraportal islet transplantation has proven to be efficacious in preventing severe
hypoglycemia and restoring insulin independence in selected patients with type 1 diabetes …

Post-liver transplantation diabetes mellitus (PLTDM) develops in up to 30% of liver
transplant recipients and is associated with increased risk of mortality and multiple morbid …

Understanding individual susceptibility to drug-induced cardiotoxicity is key to improving
patient safety and preventing drug attrition. Human induced pluripotent stem cells (hiPSCs) …

A bioartificial endocrine pancreas is proposed as a future alternative to current treatment
options. Patients with insulin-secretion deficiency might benefit. This is the first systematic …

The metabolic syndrome (MS), which includes obesity, dyslipidaemia, hypertension and
hyperglycaemia according to the most widely accepted definitions now used, is one of the …

Among other factors, sophistication of immunosuppressive (IS) regimen accounts for the
remarkable success attained in the short-and medium-term solid organ transplant (SOT) …

New-onset diabetes after transplantation is a common complication that reduces recipient
survival. Research in renal transplant recipients has suggested that pancreatic β-cell …

New-onset diabetes after transplantation (NODAT) refers to the occurrence of diabetes in
previously nondiabetic persons after organ transplantation. The incidence rates of NODAT …

Patients who undergo solid organ transplantation may have preexisting diabetes mellitus
(DM), which puts them at increased risk from any surgery. 1 It is important to evaluate the …

Up to 40% of transplant recipients treated long-term with tacrolimus (TAC) develop post-
transplant diabetes mellitus (PTDM). TAC is an important risk factor for PTDM, but is also …